A 12-month, Phase 3, Open-label, Multi-center Study to Evaluate the Long-term Safety of PN400 (VIMOVO)
Status:
Completed
Trial end date:
2009-03-01
Target enrollment:
Participant gender:
Summary
This study uses an open-label design and will be conducted in approximately 60 sites aiming
to enroll a total number of 200 subjects to ensure that at least 100 subjects will have 12
months exposure to PN400 (VIMOVO).